Targeting mitochondrial energy and lipid changes to treat relapsed AML
Official title: Therapeutic Targeting of Mitochondrial OxPhos and Lipid Remodeling in Relapsed AML
Funded at University of Texas at Austin · NIH-11440946 · Data updated 2026-11-12
A patient-focused study to see if blocking mitochondrial energy use and certain lipid processes can help people whose AML has come back or resisted treatment.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project start | August 26, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $429,471 |
| NIH project number | 1R21CA318045-01 |
| Project ID | NIH-11440946 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with AML who have relapsed after frontline therapy or have resistant disease and have sufficient health to participate in laboratory studies and potential future trials.
✕Less likely to help
Patients whose AML does not depend on the targeted metabolic pathways or who cannot tolerate the proposed therapies may not benefit.
What this research studies
This project looks at how AML cells rely on mitochondria and lipid pathways after relapse and resistance. Researchers will test combinations that inhibit glutaminase and aldehyde dehydrogenase to disrupt the cancer cells’ energy, antioxidant defenses, and lipid building blocks. The work uses lab models and patient-derived data to understand how these metabolic changes affect treatment response and survival. If successful, the approach could guide new therapeutic options for relapsed AML patients.
Why it matters
Potential benefit: If proven effective, this approach could lead to new treatments that improve responses and survival for people with relapsed AML.
How similar studies have gone: Prior studies suggest metabolic targeting can influence AML sensitivity to treatment and have shown promising preclinical synergy.
Where this research is happening
-
University of Texas at Austin
Austin, United States Active
Researchers
- Principal investigator: Tiziani, Stefano — University of Texas at Austin
- Study coordinator: Tiziani, Stefano
Related research
Other NIH-funded projects on the same topics.
-
Translating new nerve grafts to clinical use
Aims to bring advanced nerve graft technology that uses PEG-fusion and localized immunosuppression to patients with nerve gaps.
-
GABA-A receptor gating mechanisms and how drugs affect them
Researchers are studying how GABA-A receptor gates work and how medicines can modulate them to help people with epilepsy, Alzheimer's-related symptoms, and other brain disorders.
-
Nanoparticles that calm inflammation after artery procedures
A new nanoparticle inspired by dying cells is being tested to reduce inflammation after artery procedures and help PAD patients heal better.
-
Silent speech interface using a wearable tongue tracker to help people after laryngectomy communicate
A wearable system with tongue sensors and intraoral components aims to let people without a vocal cord use natural-sounding speech in daily life.
-
Understanding and reversing abnormal brain activity in Alzheimer's disease
Aims to understand how unusual brain activity contributes to Alzheimer’s and test ways to reverse it to help people with the condition.
-
CFDE Cloud Workspace to help researchers share and analyze data
A cloud-based workspace will let a wide range of researchers import, integrate, and analyze data from CFDE and other sources using familiar tools and workflows.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.